DNA Biomed Current Asset vs. Total Asset
| DNA Stock | ILS 89.60 1.00 1.10% |
For DNA Biomed profitability analysis, we use financial ratios and fundamental drivers that measure the ability of DNA Biomed to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well DNA Biomed Solns utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between DNA Biomed's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of DNA Biomed Solns over time as well as its relative position and ranking within its peers.
DNA |
DNA Biomed Solns Total Asset vs. Current Asset Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining DNA Biomed's current stock value. Our valuation model uses many indicators to compare DNA Biomed value to that of its competitors to determine the firm's financial worth. DNA Biomed Solns is one of the top stocks in current asset category among related companies. It is one of the top stocks in total asset category among related companies fabricating about 2.10 of Total Asset per Current Asset. Comparative valuation analysis is a catch-all model that can be used if you cannot value DNA Biomed by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for DNA Biomed's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the DNA Biomed's earnings, one of the primary drivers of an investment's value.DNA Total Asset vs. Current Asset
Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
DNA Biomed |
| = | 26 M |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
DNA Biomed |
| = | 54.62 M |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
DNA Total Asset Comparison
DNA Biomed is currently under evaluation in total asset category among related companies.
DNA Biomed Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in DNA Biomed, profitability is also one of the essential criteria for including it into their portfolios because, without profit, DNA Biomed will eventually generate negative long term returns. The profitability progress is the general direction of DNA Biomed's change in net profit over the period of time. It can combine multiple indicators of DNA Biomed, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
D.N.A Biomedical Solutions Ltd. develops and commercializes laser spectrometry-based trace detection systems in Israel. D.N.A Biomedical Solutions Ltd. was founded in 2004 and is based in Ramat Gan, Israel. D N operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange.
DNA Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on DNA Biomed. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of DNA Biomed position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the DNA Biomed's important profitability drivers and their relationship over time.
Use DNA Biomed in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DNA Biomed position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DNA Biomed will appreciate offsetting losses from the drop in the long position's value.DNA Biomed Pair Trading
DNA Biomed Solns Pair Trading Analysis
The ability to find closely correlated positions to DNA Biomed could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DNA Biomed when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DNA Biomed - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DNA Biomed Solns to buy it.
The correlation of DNA Biomed is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DNA Biomed moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DNA Biomed Solns moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DNA Biomed can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your DNA Biomed position
In addition to having DNA Biomed in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Baby Boomer Prospects Thematic Idea Now
Baby Boomer Prospects
Equities with large market capitalization that account for significant contribution to overall economic growth especially within dividend-paying instruments and stocks from healthcare and financial sectors. The Baby Boomer Prospects theme has 98 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Baby Boomer Prospects Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Investing Opportunities. Note that the DNA Biomed Solns information on this page should be used as a complementary analysis to other DNA Biomed's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Complementary Tools for DNA Stock analysis
When running DNA Biomed's price analysis, check to measure DNA Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DNA Biomed is operating at the current time. Most of DNA Biomed's value examination focuses on studying past and present price action to predict the probability of DNA Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DNA Biomed's price. Additionally, you may evaluate how the addition of DNA Biomed to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |
To fully project DNA Biomed's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of DNA Biomed Solns at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include DNA Biomed's income statement, its balance sheet, and the statement of cash flows.